Education
About Us
Working with TipRanks
Follow Us
DiaSorin S.p.A. (IT:DIA)
:DIA
DIA Stock Chart & Stats
€64.32
-€0.35(-0.34%)
At close: 4:00 PM EST
€64.32
-€0.35(-0.34%)
Day’s Range― - ―
52-Week Range€58.84 - €111.40
Previous CloseN/A
Volume135.55K
Average Volume (3M)221.33K
Market Cap
€3.47B
Enterprise Value€5.57B
Total Cash (Recent Filing)€182.96M
Total Debt (Recent Filing)€769.18M
Price to Earnings (P/E)18.1
Beta0.42
Next Earnings
Mar 18, 2026EPS Estimate
1.03Next Dividend Ex-DateN/A
Dividend Yield1.87%
Share Statistics
EPS (TTM)0.89
Shares Outstanding55,948,257
10 Day Avg. Volume225,158
30 Day Avg. Volume221,334
Financial Highlights & Ratios
PEG Ratio1.70
Price to Book (P/B)3.09
Price to Sales (P/S)4.69
P/FCF Ratio23.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€78.50Price Target Upside22.05% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDiaSorin reported 4Q results which were a slight beat vs Consensus on Topline and EBITDA, starting the year on a solid footing backdrop considered.
Growth OutlookManagement also pointed to ~25% combined yoy growth for the Verigene and LIAISON PLEX to around €75m, which implies low-teens growth for FY25 in Molecular Diagnostics for FY25, which serves as a solid departure point into FY25.
Bears Say
Market SurprisesThe headline of a lower Molecular Diagnostic 4Q into a strong respiratory season took us by surprise.
Regional Growth DisparityEuropean growth slowed to 4% CER, with US growing 15%, effectively normalising above average growth driven by high market share tests.
DiaSorin S.p.A. News
DIA FAQ
What was DiaSorin S.p.A.’s price range in the past 12 months?
DiaSorin S.p.A. lowest stock price was €58.84 and its highest was €111.40 in the past 12 months.
What is DiaSorin S.p.A.’s market cap?
DiaSorin S.p.A.’s market cap is €3.47B.
When is DiaSorin S.p.A.’s upcoming earnings report date?
DiaSorin S.p.A.’s upcoming earnings report date is Mar 18, 2026 which is in 88 days.
How were DiaSorin S.p.A.’s earnings last quarter?
DiaSorin S.p.A. released its earnings results on Nov 05, 2025. The company reported €0.888 earnings per share for the quarter, missing the consensus estimate of €1.002 by -€0.114.
Is DiaSorin S.p.A. overvalued?
According to Wall Street analysts DiaSorin S.p.A.’s price is currently Undervalued.
Does DiaSorin S.p.A. pay dividends?
DiaSorin S.p.A. pays a Annually dividend of €1.2 which represents an annual dividend yield of 1.87%. See more information on DiaSorin S.p.A. dividends here
What is DiaSorin S.p.A.’s EPS estimate?
DiaSorin S.p.A.’s EPS estimate is 1.03.
How many shares outstanding does DiaSorin S.p.A. have?
DiaSorin S.p.A. has 55,948,257 shares outstanding.
What happened to DiaSorin S.p.A.’s price movement after its last earnings report?
DiaSorin S.p.A. reported an EPS of €0.888 in its last earnings report, missing expectations of €1.002. Following the earnings report the stock price went down -2.75%.
Which hedge fund is a major shareholder of DiaSorin S.p.A.?
Currently, no hedge funds are holding shares in IT:DIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DiaSorin S.p.A.
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
DIA Stock 12 Month Forecast
Average Price Target
€78.50
▲(22.05% Upside)
Technical Analysis
Recordati Industria Chimica e Farmaceutica SPA
―
PharmaNutra SpA
―
Garofalo Health Care S.P.A.
―
GPI SpA
―
Svas Biosana S.p.A.
―
Options Prices
Currently, No data available
---